Rare Disease Research
Business Services · Georgia, United States · <25 Employees
View Company Info for Free
About
Headquarters
1891 Howell Mill Rd NW Ste B, Atlanta, Georgia,...Phone Number
(678) 883-6897Website
www.rarediseaseresearch.comRevenue
<$5 MillionIndustry
Most Recent Scoops
Who is Rare Disease Research
Rare Disease Research Org Chart
Is Rare Disease Research your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Rare Disease Research recently announced quarterly report
Product Launch: Get notified when Rare Disease Research launches new products
Congratulate Masked Content for being promoted to Masked Content at Rare Disease Research
Click to see if Rare Disease Research had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Rare Disease Research has recently received funding, and reach out quickly before it becomes old news!
Check out if Rare Disease Research is spiking on competitors!
Rare Disease Research, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Rare Disease Research has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Rare Disease Research
Compare insights from companies similar to Rare Disease Research, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Rare Disease Research
Rare Disease Research Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Rare Disease Research Tech Stack
A closer look at the technologies used by Rare Disease Research
Rare Disease Research News & Media
Edgewise Therapeutics Announces Initiation of LYNX Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD)
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, today announced that it has initiated the LYNX Phase 2 clinical trial at Rare Disease Research, LLC in Atlanta, Georgia. The trial will examine the safety, pharmacokinetics (PK) and effect on biomarkers of muscle damage of EDG-5506 in children with DMD. The study wiRare STRIDES® Has Formed a Collaboration with Rare Disease Research (RDR) of Atlanta
RDR conducts clinical trials for patients with rare disease, who otherwise would not have the opportunity to receive any treatment. Rare Strides is pleased to announce a a collaboration with Rare Disease Research (RDR) of Atlanta. The collaboration will inspire students, medical teams, and patients to learn more about clinical trials and unite clinical trials. [PR.com]
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding Rare Disease Research
We are the comprehensive Contract Research Organization service provider with laser focus on accelerating global clinical development for rare diseases. Our mission is to collaborate with all sizes of biotech companies ranging from those who are at start-up phase to those with full scale clinical development pipeline at by expedite clinical trials... Read More